Dyne Therapeutics, Inc.

NASDAQ:DYN

Biotechnology

Healthcare
$15.87 +1.97%

+$0.38 today

Market cap
$2.97B
Beta
1.08
P/E (TTM)
-7.2
EPS (TTM)
-$2.74
52W Low $8.06High $25.00

Volume 2.93M

Average 1.71M

DYN Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Dyne Therapeutics, Inc.NASDAQ: DYN

Other Income / Expenses · Q2 FY2026 · quarter ended Jun 2026

Other income / expenses declines year over year

Q2 FY2026 other income / expenses of $3.11M fell 37.1% year over year, in line with the -37.4% change in trailing-twelve-month other income / expenses. Sequentially, it fell 29.8% from the prior quarter. Over 3 fiscal years it compounded at +97.2% a year.

Context

  • Other income / expenses increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -37.1% holds above the trailing-twelve-month pace of -37.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$3.11M-29.8% QoQ
Last fiscal yearDec 2025
$21.97M-17.0% YoY
LTMJun 2026
$17.55M-37.4% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-37.1%——
1 year-17.0%——
3-year CAGR+97.2%——
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
21.97M USD
Year-over-year change
-17.0%
4-year CAGR
+133.9%

Other Income / Expenses vs competitors

How DYN compares with its peers on the latest reported figures

  • DYN's LTM Jun 2026 other income / expenses of $17.55M is the 3rd highest of the 11 companies compared; the peer median is $9.84M.
  • Its year-over-year change of -37.4% is the 10th highest of 11, against a peer median of +2.9%.
  • Over three fiscal years its annual growth of +97.2% compares with a peer median of +63.4%.
DYN Competitors Peer median
Other Income / Expenses for DYN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SRPTSarepta Therapeutics, Inc.LTM Mar 2026$65.43M +239.3%—3.0%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$21.61M +11.8%-76.4%2.3%
DYNDyne Therapeutics, Inc.LTM Jun 2026$17.55M -37.4%+97.2%—
STOKStoke Therapeutics, Inc.LTM Mar 2026$14.2M +6.7%+60.9%44.3%
WVEWave Life Sciences Ltd.LTM Mar 2026$13.29M -1.0%+91.1%18.5%
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$13.26M -32.7%+71.0%231.0%
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$6.42M -36.5%+80.0%—
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$5.34M +140.8%+66.0%—
SLDBSolid Biosciences Inc.LTM Mar 2026$4.68M +44.4%-38.0%—
PEPGPepGen Inc.LTM Mar 2026$4.08M -37.0%+11.3%—
PTCTPTC Therapeutics, Inc.LTM Jun 2026-$183.33M -250.6%—18.2%
Peer median (excluding DYN) $9.84M+2.9%+63.4%18.3%

Competitors are the stored peer set for DYN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue002.46M2.24M2.05M
Gross Profit00(2.46M)(2.24M)(2.05M)
Gross Margin—————
Research & Development121.31M142.76M210.76M281.41M398.33M
Selling, General & Admin28.72M28.2M31.4M62.48M69.85M
Operating Expenses150.03M170.96M239.7M341.64M466.14M
Depreciation & Amortization1.09M1.68M1.67M1.67M2.05M
EBITDA(148.2M)(163.5M)(234.26M)(315.75M)(437.97M)
EBITDA Margin—————
Operating Income(150.03M)(170.96M)(242.16M)(343.89M)(468.18M)
Operating Margin—————
Interest Income742K2.92M7.64M26.92M29.86M
Interest Expense02.92M006.19M
Other Income / Expenses734K2.86M6.23M26.47M21.97M
Income Before Tax(149.29M)(168.1M)(235.94M)(317.42M)(446.21M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(149.29M)(168.1M)(235.94M)(317.42M)(446.21M)
Net Margin—————
EPS (Basic)(2.93)(3.23)(3.95)(3.37)(3.47)
EPS (Diluted)(2.93)(3.23)(3.95)(3.37)(3.47)
Weighted Avg Shares50.9M51.98M59.68M94.14M128.44M
Weighted Avg Shares (Diluted)50.9M51.98M59.68M94.14M128.44M

Dyne Therapeutics, Inc.

NASDAQ:DYN

Intrinsic Alpha fair value

Locked

Current Price

$15.87

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.